Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.

NCT03084471 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03084471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03084471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
June 5, 2017
Completion date
December 16, 2022
Enrollment
867 (actual)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid malignancies